VPT:CC - ASCEND Cardiovascular to Market and Distribute Ventripoint's AI-powered Heart-Scanning Technology to North American Hospitals and Clinics

(TheNewswire)

Highlights of agreement

• ASCEND’s IT software is used by 50,000 hospitals,clinics, and caregivers.

• Initial two-year term for North Americanmarkets.

• Ventripoint will be integrated into ASCEND’s IT forcardiovascular care.

Toronto, Ontario – TheNewswire - December 12, 2023 -Ventripoint Diagnostics Ltd. (" Ventripoint " orthe " Company "), (TSXV:VPT ) ( OTC:VPTDF), now bringing itsAI-powered heart-scanning technology to the world’s hospitals, ispleased to announce it has entered into a global distribution andmarketing agreement with A SCEND Cardiovascular (“A SCEND ”) .

A SCEND Cardiovascular is a leader in offering cutting-edge diagnostic, andimaging technologies and workflows to improve cardiac health care.A SCEND is trusted by AGFAHealthcare, Sectra, Oracle/ Cerner, and other major players in the healthcare system. Its technology stack has been integrated intothe workflows of 1,000+ top-ranked healthcare facilities and 600+health systems, representing a user base of 50,000 who serve millionsof heart patients.

A SCEND willmarket and distribute Ventripoint’s AI-powered heart-scanningtechnology, which turns ultrasound images of the heart intoMRI-quality heart images. Using AI, and the images from existingultrasound systems of any brand, Ventripoint creates these MRI-qualityheart images at a fraction of the cost and time needed for moretraditional heart MRIs. “ After many years of careful research and development, and rigorousin-hospital testing, Ventripoint’s heart-imaging technology withA SCEND ’s proven support is ready for theworld’s hospitals and he a rt patients ,” said Dr. Alvira Macanovic,President & CEO of Ventripoint. “ With this A SCEND partnership I am encouraged we will winthe confidence of hospitals and cardiologists across North America andbeyond .”

“ We arelooking forward to the partnership between Ventripoint Diagnostics andA SCEND Cardiovascular. Our aim is that byworking together, we can ultimately provide reliable and effectivetools for clinicians on a global scale ,”stated Jeffrey Soble, MD, ASCEND’s President and CEO.

The global distribution agreement has an initialtwo-year term, with ASCEND as the official reseller. A SCEND will market and sell theVentripoint VMS+ system as part of its inclusive solution, as well asintegration with A SCEND ’s cardiovascular IT platform.

Ventripoint will be providing support and training toASCEND on the use and capabilities of the VMS+ during the term of theagreement. The collaboration between Ventripoint and ASCEND willreduce time to market and overall effort to provide new softwaresolutions to the market.

“ Combiningthese two products creates an end-to-end solution rivaling the besttechnology offered on the market , said Dr.Macanovic. “ Our partnershipincludes joint research and development initiatives to optimizecurrent technologies and exploratory projects to identify new treatmentpossibilities, reduce waiting times, and ensure a cost-effectiveaddition to the heart healthcare system .”

Ventripoint, nowcommercializing its technology, has won accolades from leadinghospitals, and the British Heart Foundation and has drawn international media attention . As the relationship betweenVentripoint and ASCEND Cardiovascular continues to evolve, bothcompanies remain committed to driving innovation and excellence incardiovascular health technology.

About Ventripoint DiagnosticsLtd.

Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe, and Canada. Learn more: www.ventripoint.com .

About ASCEND Cardiovascular

ASCEND Cardiovascular is a leader in innovatingcardiovascular solutions that empower the provider community toimprove cardiovascular care. Designed with openness in mind, oursolutions integrate with EHRs, medical devices, and other systems todeliver seamless workflows that span procedure types and modalities. Acomplete cardiovascular solution, ASCEND provides structuredreporting, image visualization, collaboration, and analytics thatimprove efficiency, outcomes, and ROI. With decades of experience anda practicing cardiologist at our helm, the ASCEND team bringsunparalleled “know how” in cardiology workflow, collaboration, andIT offering limitless opportunities to improve clinical, operational,and quality performance. Learn more: www.ascendcv.com .

For further information, pleasecontact:

Jonathan Robinson CFA

JRobinson@oakhillfinancial.ca

(416) 669-1001

Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.

Forward Looking Statements

This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.

Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.

Copyright (c) 2023 TheNewswire - All rights reserved.